Horizon Pharma PLC Company Profile (NASDAQ:HZNP)

About Horizon Pharma PLC

Horizon Pharma PLC logoHorizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units. Its segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. Its marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). It also developed DUEXIS and RAYOS, known as LODOTRA.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: HZNP
  • CUSIP: 44047T10
Key Metrics:
  • Previous Close: $17.15
  • 50 Day Moving Average: $16.84
  • 200 Day Moving Average: $18.29
  • 52-Week Range: $161,257,000.00 - $13.05
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 7.36
  • P/E Growth: 0.47
  • Market Cap: $2.81B
  • Outstanding Shares: 161,257,000
  • Beta: 1.76
Profitability:
  • Net Margins: -1.34%
  • Return on Equity: 22.73%
  • Return on Assets: 9.38%
Debt:
  • Debt-to-Equity Ratio: 0.84%
  • Current Ratio: 2.01%
  • Quick Ratio: 1.72%
Additional Links:
Companies Related to Horizon Pharma PLC:

Analyst Ratings

Consensus Ratings for Horizon Pharma PLC (NASDAQ:HZNP) (?)
Ratings Breakdown: 1 Hold Rating, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.91)
Consensus Price Target: $29.82 (70.88% upside)

Analysts' Ratings History for Horizon Pharma PLC (NASDAQ:HZNP)
Show:
DateFirmActionRatingPrice TargetDetails
2/22/2017MizuhoReiterated RatingBuy$25.00View Rating Details
12/18/2016Jefferies Group LLCSet Price TargetBuy$26.00View Rating Details
12/8/2016BMO Capital MarketsReiterated RatingOutperform$29.00 -> $24.00View Rating Details
11/28/2016Citigroup Inc.UpgradeNeutral -> BuyView Rating Details
10/12/2016Goldman Sachs Group, Inc. (The)Set Price TargetBuy$26.00View Rating Details
9/28/2016Morgan StanleyReiterated RatingHold$24.00View Rating Details
9/12/2016Brean CapitalReiterated RatingBuy$32.00View Rating Details
9/12/2016Cowen and CompanyReiterated RatingOutperform -> Outperform$42.00View Rating Details
8/23/2016GuggenheimReiterated RatingBuy$30.00View Rating Details
8/10/2016Piper Jaffray CompaniesReiterated RatingOverweight$34.00 -> $33.00View Rating Details
7/6/2016Stifel NicolausReiterated RatingBuy$45.00View Rating Details
11/11/2015WallachBeth CapitalUpgradeBuyView Rating Details
10/22/2015JMP SecuritiesReiterated RatingBuyView Rating Details
7/7/2015Leerink SwannReiterated RatingPositive$37.00View Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Horizon Pharma PLC (NASDAQ:HZNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2017Q416$0.50$307.93 millionN/AView Earnings Details
11/7/2016Q316$0.63$0.70$270.04 million$273.70 millionViewListenView Earnings Details
8/8/2016Q216$0.50$0.62$235.43 million$257.40 millionViewN/AView Earnings Details
5/9/2016Q116$0.30$0.34$197.73 million$204.70 millionViewN/AView Earnings Details
2/29/2016Q415$0.62$0.63$240.92 million$244.50 millionViewListenView Earnings Details
11/6/2015Q315$0.40$0.70$185.70 million$292.70 millionViewListenView Earnings Details
8/7/2015Q215$0.32$0.39$156.41 million$172.80 millionViewListenView Earnings Details
5/8/2015Q115$0.21$0.21$104.20 million$113.10 millionViewN/AView Earnings Details
2/27/2015Q414$0.23$0.27$95.50 million$103.80 millionViewN/AView Earnings Details
11/6/2014Q314$0.17$0.24$73.17 million$75.10 millionViewN/AView Earnings Details
8/7/2014Q214$0.10$0.21$58.35 million$66.10 millionViewN/AView Earnings Details
5/9/2014Q114$0.01$0.16$42.69 million$51.90 millionViewN/AView Earnings Details
3/13/2014Q413($0.08)($0.22)$32.20 million$43.10 millionViewN/AView Earnings Details
11/8/2013Q3 13($0.25)($0.03)$18.31 million$31.50 millionViewN/AView Earnings Details
8/9/2013Q213($0.32)($0.24)$16.09 million$17.64 millionViewN/AView Earnings Details
5/10/2013Q113($0.35)($0.30)$9.47 million$9.20 millionViewN/AView Earnings Details
11/13/2012Q312($0.68)($0.39)$4.12 million$7.20 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Horizon Pharma PLC (NASDAQ:HZNP)
Current Year EPS Consensus Estimate: $2.02 EPS
Next Year EPS Consensus Estimate: $2.37 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.58$0.58$0.58
Q2 20161$0.49$0.49$0.49
Q3 20161$0.65$0.65$0.65
Q4 20161$0.55$0.55$0.55
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Horizon Pharma PLC (NASDAQ:HZNP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Horizon Pharma PLC (NASDAQ:HZNP)
Insider Ownership Percentage: 2.10%
Institutional Ownership Percentage: 88.09%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/2/2016Jeffrey W. ShermanEVPSell2,900$20.00$58,000.00View SEC Filing  
6/15/2016Virinder NohriaDirectorSell25,000$17.69$442,250.00View SEC Filing  
2/26/2016Jeffrey W ShermanEVPSell4,100$20.00$82,000.00View SEC Filing  
12/10/2015Jeffrey W ShermanEVPSell4,456$20.00$89,120.00View SEC Filing  
9/21/2015Jeffrey W ShermanEVPSell7,750$31.78$246,295.00View SEC Filing  
7/15/2015Jeffrey W ShermanEVPSell26,887$35.55$955,832.85View SEC Filing  
3/13/2015Jeff HimawanDirectorSell554,564$22.44$12,444,416.16View SEC Filing  
3/10/2015Jeff HimawanDirectorSell1,614,827$21.85$35,283,969.95View SEC Filing  
11/19/2014Jeff HimawanDirectorSell3,450,000$12.05$41,572,500.00View SEC Filing  
11/19/2014Jeffrey W ShermanEVPSell24,999$12.05$301,237.95View SEC Filing  
11/19/2014Timothy P WalbertCEOSell150,000$12.05$1,807,500.00View SEC Filing  
11/13/2014Balaji VenkataramanMajor ShareholderSell6,086,957$11.54$70,243,483.78View SEC Filing  
11/13/2014Virinder NohriaDirectorSell1,739,130$11.54$20,069,560.20View SEC Filing  
9/30/2014Vaere Robert J DeCFOSell51,942$12.28$637,847.76View SEC Filing  
5/19/2014Timothy WalbertCEOSell31,742$12.94$410,741.48View SEC Filing  
5/19/2014Todd SmithEVPSell10,159$12.94$131,457.46View SEC Filing  
5/19/2014Vaere Robert DeCFOSell12,939$12.94$167,430.66View SEC Filing  
12/13/2013Jeffrey BirdDirectorBuy668,673$6.50$4,346,374.50View SEC Filing  
12/9/2013Timothy WalbertCEOSell12,124$6.79$82,321.96View SEC Filing  
12/9/2013Todd SmithEVPSell11,322$6.91$78,235.02View SEC Filing  
11/21/2013Jeffrey BirdDirectorBuy151,089$6.24$942,795.36View SEC Filing  
9/25/2012Jeffrey W BirdDirectorBuy575,356$3.49$2,007,992.44View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Horizon Pharma PLC (NASDAQ:HZNP)
DateHeadline
realistinvestor.com logoMean Rating Of Horizon Pharma plc (NASDAQ:HZNP) At $1.29 (NASDAQ:HZNP)
www.realistinvestor.com - February 23 at 5:49 PM
finance.yahoo.com logoHorizon (HZNP) Q4 Earnings: Stock Likely to Disappoint? (NASDAQ:HZNP)
finance.yahoo.com - February 23 at 5:49 PM
streetinsider.com logoMizuho Reiterates Buy Rating and $25 PT on Horizon Pharma (HZNP) Ahead of 2/27 4Q16 Report (NASDAQ:HZNP)
www.streetinsider.com - February 22 at 12:45 PM
News IconImpact of Brokerage Rating on Horizon Pharma PLC(HZNP) - Highland Mirror (NASDAQ:HZNP)
www.highlandmirror.com - February 17 at 3:17 PM
News IconHorizon Pharma plc (NASDAQ:HZNP) Daily Sentiment Score At 0.041 - Stock Observer (NASDAQ:HZNP)
www.thestockobserver.com - February 17 at 3:17 PM
News IconAnalysts Take Aim At This Stock's Earnings Estimates: Horizon Pharma plc (NASDAQ:HZNP) - Aiken Advocate (NASDAQ:HZNP)
aikenadvocate.com - February 15 at 12:10 AM
finance.yahoo.com logoHorizon Pharma plc to Participate in Cowen and Company 37th Annual Health Care Conference (NASDAQ:HZNP)
finance.yahoo.com - February 14 at 7:09 PM
capitalcube.com logoHorizon Pharma Plc – Value Analysis (NASDAQ:HZNP) : February 14, 2017 (NASDAQ:HZNP)
www.capitalcube.com - February 14 at 7:09 PM
News IconHorizon Pharma plc (NASDAQ:HZNP) Mean Price Target At $30.428 - Transcript Daily (NASDAQ:HZNP)
transcriptdaily.com - February 12 at 10:40 PM
News IconForward Earnings Estimate of Horizon Pharma PLC(HZNP) - Highland Mirror (NASDAQ:HZNP)
www.highlandmirror.com - February 11 at 5:52 PM
News IconHorizon Pharma plc (NASDAQ:HZNP) Target Price At $30.428 - Transcript Daily (NASDAQ:HZNP)
transcriptdaily.com - February 8 at 6:31 PM
News IconHorizon Pharma plc (NASDAQ:HZNP) Bearish Target At $42 - Stock Observer (NASDAQ:HZNP)
www.thestockobserver.com - February 5 at 5:32 PM
News IconEPS Target Of Horizon Pharma plc (NASDAQ:HZNP)Set At $0.94 - Transcript Daily (NASDAQ:HZNP)
transcriptdaily.com - February 5 at 5:32 PM
realistinvestor.com logoHorizon Pharma plc (NASDAQ:HZNP) Mean Rating At $1.29 (NASDAQ:HZNP)
www.realistinvestor.com - February 2 at 6:30 PM
News IconBeach Point Capital Management LP Has Decreased Its Horizon Pharma Plc (HZNP) Stake by $14.35 Million (NASDAQ:HZNP)
randolphguide.com - February 2 at 6:30 PM
News IconEPS Forecast Of Horizon Pharma plc (NASDAQ:HZNP) Set At $0.94 - Transcript Daily (NASDAQ:HZNP)
transcriptdaily.com - February 1 at 11:40 PM
News IconNoticeable Stocks to Watch: Horizon Pharma plc (NASDAQ:HZNP ... - The Newburgh Press (NASDAQ:HZNP)
newburghpress.com - January 30 at 11:04 AM
News IconStock's Buzz: Horizon Pharma plc (NASDAQ:HZNP), Spirit Realty Capital, Inc. (NYSE:SRC) - The Newburgh Press (NASDAQ:HZNP)
newburghpress.com - January 27 at 9:41 PM
marketnewsvideo.com logoNotable Friday Option Activity: MIC, MSFT, HZNP (NASDAQ:HZNP)
www.marketnewsvideo.com - January 27 at 4:41 PM
finance.yahoo.com logoHorizon Pharma plc to Host Fourth-Quarter 2016 Conference Call and Webcast on February 27, 2017 (NASDAQ:HZNP)
finance.yahoo.com - January 27 at 4:40 PM
realistinvestor.com logoHorizon Pharma plc (NASDAQ:HZNP) Deferred Tax Assets At $13.196 Millions - RealistInvestor.com (NASDAQ:HZNP)
www.realistinvestor.com - January 26 at 7:28 PM
News IconHorizon Pharma plc (NASDAQ:HZNP) Closed the Last Trading Session at $16.5 - The Newburgh Press (NASDAQ:HZNP)
newburghpress.com - January 26 at 7:28 PM
News IconEarnings in Full Force, Analysts Take Aim at Horizon Pharma plc (NASDAQ:HZNP) - Wall Street Beacon (NASDAQ:HZNP)
wsbeacon.com - January 26 at 7:28 PM
realistinvestor.com logoMean Rating Of Horizon Pharma plc (NASDAQ:HZNP) At $1.29 - RealistInvestor.com (NASDAQ:HZNP)
www.realistinvestor.com - January 26 at 7:28 PM
News IconConsensus Price Of Horizon Pharma plc (NASDAQ:HZNP) Set At $30.714 - Transcript Daily (NASDAQ:HZNP)
transcriptdaily.com - January 26 at 5:16 AM
News IconQuarterly EPS Of Horizon Pharma plc (NASDAQ:HZNP) Set At $0.94 - Stock Observer (NASDAQ:HZNP)
www.thestockobserver.com - January 26 at 5:16 AM
News IconHealthcare Stocks Ringing Investment Alarms: Infinity Pharmaceuticals, Inc. (NASDAQ:INFI), Horizon Pharma plc ... - Street Wise Report (press release) (blog) (NASDAQ:HZNP)
streetwisereport.com - January 24 at 6:33 PM
seekingalpha.com logoAurinia Pharmaceuticals Is Now An Attractive Buyout Candidate (NASDAQ:HZNP)
seekingalpha.com - January 23 at 6:04 PM
News IconCCI, MA, and RSI in Focus for Horizon Pharma Inc. (HZNP) - Rives Journal (NASDAQ:HZNP)
rivesjournal.com - January 23 at 10:58 AM
News IconNoteworthy Friday Option Activity: HZNP, AMBA, MAR (NASDAQ:HZNP)
www.stockoptionschannel.com - January 20 at 4:02 PM
News IconGlobal Genes® and Horizon Pharma plc Partner to Offer Nephropathic Cystinosis Scholarships (NASDAQ:HZNP)
www.yahoo.com - January 17 at 12:16 PM
investornewswire.com logoSentiments And Ratings Alert: Horizon Pharma plc (NASDAQ:HZNP) - Investor Newswire (NASDAQ:HZNP)
www.investornewswire.com - January 12 at 6:17 PM
realistinvestor.com logoHorizon Pharma plc (NASDAQ:HZNP) Mean Rating At $1.29 - RealistInvestor.com (NASDAQ:HZNP)
www.realistinvestor.com - January 12 at 6:17 PM
News IconWill The Needle Move For Horizon Pharma plc (NASDAQ:HZNP) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:HZNP)
wsbeacon.com - January 12 at 6:17 PM
News IconAnalyst Issues Short Term Price Target on Horizon Pharma plc (NASDAQ:HZNP) - Highland Mirror (NASDAQ:HZNP)
www.highlandmirror.com - January 12 at 6:17 PM
News IconHorizon Pharma plc (NASDAQ:HZNP) Quarterly EPS Set At $0.94 - Stock Observer (NASDAQ:HZNP)
www.thestockobserver.com - January 11 at 11:29 PM
seekingalpha.com logoHorizon Pharma (HZNP) presents at 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:HZNP)
seekingalpha.com - January 11 at 6:27 PM
capitalcube.com logoHorizon Pharma Plc breached its 50 day moving average in a Bullish Manner : HZNP-US : January 11, 2017 (NASDAQ:HZNP)
www.capitalcube.com - January 11 at 6:27 PM
News IconStocks Buzz: Cousins Properties Incorporated (NYSE:CUZ), Horizon Pharma plc (NASDAQ:HZNP) - The Newburgh Press (NASDAQ:HZNP)
newburghpress.com - January 10 at 6:43 PM
biz.yahoo.com logoHORIZON PHARMA PLC Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:HZNP)
biz.yahoo.com - January 10 at 6:43 PM
seekingalpha.com logoHorizon Pharma +2.4% ahead of conference presentation (NASDAQ:HZNP)
seekingalpha.com - January 10 at 9:56 AM
News IconHORIZON PHARMA IRELAND LIMITED v. ACTAVIS LABORATORIES, UT, INC. (NASDAQ:HZNP)
www.leagle.com - January 9 at 6:32 PM
capitalcube.com logoETFs with exposure to Horizon Pharma Plc : January 9, 2017 (NASDAQ:HZNP)
www.capitalcube.com - January 9 at 6:32 PM
News IconLong-Term Growth Estimate Of Horizon Pharma plc (NASDAQ:HZNP) At $18 - Transcript Daily (NASDAQ:HZNP)
transcriptdaily.com - January 8 at 10:38 PM
realistinvestor.com logoResearch Analysts Set Horizon Pharma plc (NASDAQ:HZNP) Price Target at $30.714 (NASDAQ:HZNP)
www.realistinvestor.com - January 5 at 7:01 PM
News IconTechnical Reports on Generic Drugs Stocks -- Mylan, Allergan, Horizon Pharma, and Catalent (NASDAQ:HZNP)
www.kait8.com - January 4 at 4:51 PM
News IconHorizon Pharma plc (NASDAQ:HZNP) Consensus Price At $ 30.714 - Transcript Daily (NASDAQ:HZNP)
transcriptdaily.com - January 3 at 11:41 AM
News IconUpside Alert: Delving into Shares of Horizon Pharma plc (NASDAQ:HZNP) - Prospect Journal (NASDAQ:HZNP)
prospectjournal.com - January 3 at 11:41 AM
News IconBearish Target Of Horizon Pharma plc (NASDAQ:HZNP) At $42 - Stock Observer (NASDAQ:HZNP)
www.thestockobserver.com - January 2 at 7:01 AM
nasdaq.com logoCommit To Purchase Horizon Pharma At $13, Earn 15.9% Annualized Using Options (NASDAQ:HZNP)
www.nasdaq.com - December 29 at 5:52 PM

Social

What is Horizon Pharma PLC's stock symbol?

Horizon Pharma PLC trades on the NASDAQ under the ticker symbol "HZNP."

Where is Horizon Pharma PLC's stock going? Where will Horizon Pharma PLC's stock price be in 2017?

11 brokerages have issued 1-year target prices for Horizon Pharma PLC's stock. Their forecasts range from $21.00 to $45.00. On average, they expect Horizon Pharma PLC's share price to reach $29.82 in the next twelve months.

When will Horizon Pharma PLC announce their earnings?

Horizon Pharma PLC is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.

What are analysts saying about Horizon Pharma PLC stock?

Here are some recent quotes from research analysts about Horizon Pharma PLC stock:

  • Mizuho analysts commented, "We are positive on HZNP ahead of the February 27 earnings call: We think the company may deliver a 4Q:16 earnings beat. We model 4Q:16 revenues of $325.4M and EPS of $0.57 relative to consensus $308.5M and $0.50 and implied guidance $309-$314M. Horizon has delivered strong beats in the past and we expect adjusted EBITDA to approach the higher end of the guidance range of $450-$460M. With respect to 2017 guidance, we fall below FactSet consensus estimates of $1,289.7M and $2.39 (we model $1,281.8M and $2.29), but note that Horizon may be able to beat this range via a combination of both price and volume growth, so guidance could come in stronger than expected. There is still significant uncertainty around business operation under the new PBM contracts, gross to net discounts, infrastructure needs, and the timing of anticipated volume growth. We therefore expect the focus of the call to be around these issues as well as on future business development targets and pipeline outlook." (2/22/2017)
  • According to Zacks Investment Research, "Horizon’s growth-by-acquisition strategy, through which it actively pursues deals to expand and diversify its portfolio, is encouraging. The Raptor Pharma acquisition to strengthen its rare disease business is impressive. Moreover, the Hyperion and Crealta acquisitions bode well. However, the company’s efforts to expand Actimmune’s label suffered a developmental setback. Actimmune failed in a late-stage Friedreich's ataxia study, which could have given its sales a much-needed boost. Horizon is also involved in patent litigations with quite a few companies. Also, Horizon’s marketed products face intense competition. Pipeline setbacks, competitive pressures, concerns related to the ongoing litigations and focus on drug pricing remain material headwinds. The company has a negative record of earnings surprise in the last four trailing quarters while the estimates are stable ahead of Q4 results." (2/17/2017)

  • Jefferies Group LLC analysts commented, "Q2 results were well ahead of consensus (revs +10%, EPS +11%), driven by stronger revs from primary care products (+$19M vs JEF). This outperformance came despite higher than forecasted expenses (+$7M vs JEF). Mgt also reaffirmed its FY16 guidance – which appears increasingly achievable as improved GtN’s offset softening PCP Rxs." (8/4/2016)

  • Brean Capital analysts commented, "We valued Mallinckrodt via discounted cash flow analysis. We assigned the company an 11% weighted average cost of capital, since we view its commercial risk as manageable. We utilize a 2% terminal growth rate since the company has durable assets and is investing further in its pipeline." (8/2/2016)

Who owns Horizon Pharma PLC stock?

Horizon Pharma PLC's stock is owned by many different of institutional and retail investors. Top institutional investors include Deerfield Management Co. (5.55%), FMR LLC (3.54%), State Street Corp (2.69%), Janus Capital Management LLC (2.29%), Dimensional Fund Advisors LP (1.61%) and Hodges Capital Management Inc. (1.35%). Company insiders that own Horizon Pharma PLC stock include Jeff Himawan, Jeffrey W Sherman and Virinder Nohria.

Who sold Horizon Pharma PLC stock? Who is selling Horizon Pharma PLC stock?

Horizon Pharma PLC's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Fiera Capital Corp, Oxford Asset Management, Franklin Resources Inc., Janus Capital Management LLC, TCW Group Inc., Guggenheim Capital LLC and AQR Capital Management LLC. Company insiders that have sold Horizon Pharma PLC stock in the last year include Jeffrey W Sherman and Virinder Nohria.

Who bought Horizon Pharma PLC stock? Who is buying Horizon Pharma PLC stock?

Horizon Pharma PLC's stock was acquired by a variety of institutional investors in the last quarter, including Deerfield Management Co., Armistice Capital LLC, Dimensional Fund Advisors LP, Artal Group S.A., Systematic Financial Management LP, Russell Investments Group Ltd., State Street Corp and Seven Eight Capital LP.

How do I buy Horizon Pharma PLC stock?

Shares of Horizon Pharma PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Horizon Pharma PLC stock cost?

One share of Horizon Pharma PLC stock can currently be purchased for approximately $17.45.

Horizon Pharma PLC (NASDAQ:HZNP) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)

Earnings History Chart

Earnings by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)

Dividend History Chart

Dividend Payments by Quarter for Horizon Pharma PLC (NASDAQ:HZNP)

Last Updated on 2/26/2017 by MarketBeat.com Staff